Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Peter Mancini

Parent Petroleum offers hope to those with blindness

Parent Petroleum
Donor

Peter Mancini, Ann Rasch, Michael Grassi and Joseph Aliperta

On October 23, 2014, the University of Illinois at Chicago (UIC) Department of Ophthalmology and Visual Sciences welcomed Parent Petroleum to thank the company for its longstanding support and present a plaque in gratitude.

For the past 17 years, Parent Petroleum has hosted an annual golf outing to benefit vision research.  In August 2014, Parent Petroleum, along with annual lead event sponsor, BP, raised nearly $100k for vision research in the Department Ophthalmology and Visual Sciences.  This contribution funds research into treatments and cures for retinal degenerative diseases.

Michael Grassi, MD leads the multidisciplinary effort in the Retinal Chemical Genomics Laboratory which has been directly impacted by Parent Petroleum and its supporters this year.  “On behalf of those individuals affected by vision loss, I would like to recognize the extraordinary support of Parent Petroleum.  Parent’s unflagging commitment to research into the causes and treatments of blinding disease will accelerate discoveries that lead to the cures of tomorrow.   Through their generosity, Parent Petroleum, together with their sponsors, are helping to usher in a new era in the care of these patients.  Parent has become a driving force for a better future for those who are confronted with blindness,” stated Dr. Grassi.

On hand to accept the plaque from Dr. Grassi was Peter Mancini, President of Parent Petroleum;  Joseph Aliperta, Brands Coordinator for Parent Petroleum; and Ann Rasch, Community Organizer.

The University of Illinois College of Medicine Department of Ophthalmology and Visual Sciences expresses its gratitude to Parent Petroleum – its leadership, supporters, sponsors and volunteers – for continuing to support this work and making a difference in the lives of patients living with retinal degenerative disease.